Curis CRIS

NASDAQ CRIS

$1.20 -0.07 (-5.51%)

At close: Sep 9, 2026 · 4:00 PM EDT

Key Stats

Market Cap2.57 Mn

P/E-0.27

P/S0.60

Div. Yield0.00

Add ratio to table…

About

Curis is a biotechnology company focused on the development of emavusertib (CA 4948) an orally available small molecule inhibitor of IRAK4 and FLT3. The company advances this compound through clinical programs in hematologic malignancies including relapsed refractory primary central nervous system lymphoma chronic lymphocytic leukemia and acute myeloid leukemia. Curis holds orphan drug designations from the U S Food and Drug Administration and the European Commission for emavusertib in the treatment of primary central nervous system lymphoma acute myeloid leukemia and myelodysplastic syndromes. The firm maintains a worldwide exclusive license to emavusertib through its 2015 collaboration with Aurigene Discovery Technologies Limited. Curis also retains rights to additional programs under the Aurigene alliance such as the PD1 TIM3 immune checkpoint program and an undisclosed immuno oncology program. The company’s principal executive office is located in Lexington Massachusetts.

Curis generates revenue primarily through its collaboration and licensing arrangements. Under the Aurigene agreement the company is eligible to receive milestone payments tied to regulatory approval and commercial sales as well as tiered royalties on net sales of any resulting products. Aurigene may also provide supplemental funding for certain program activities. Curis is entitled to a percentage of Aurigene’s sublicensing revenues and to royalties on potential future sales of compounds such as CA 170. In addition the company has monetized existing royalty interests by selling portions of its rights to third parties for upfront cash as seen in the Oberland and TPC Investments transactions. While no product is currently commercialized the pipeline could yield future sales of emavusertib or other candidates which would create a direct revenue stream. Until such sales occur the company depends on partnership related payments and occasional equity financing to fund operations.

Curis occupies a niche within the biotechnology sector as a developer of dual targeting kinase inhibitors for blood cancers. Its lead molecule emavusertib simultaneously inhibits IRAK4 and FLT3 a mechanism that aims to overcome resistance seen with single agent FLT3 inhibitors. The company faces competition from established BTK inhibitors such as ibrutinib and zanubrutinib from FLT3 directed therapies like gilteritinib and midostaurin and from other IRAK4 focused programs emerging in the industry. Curis differentiates itself through the orphan drug designations that may confer market exclusivity if approval is achieved and through preclinical data showing synergy between IRAK4 and FLT3 blockade. The firm’s strategy of combining emavusertib with BTK inhibitors in clinical trials seeks to leverage existing standard of care while adding a novel mechanism of action.

The company’s customers are primarily patients with hematologic disorders who receive treatment in clinical trial settings or eventually through commercial channels. Curis collaborates with pharmaceutical partners such as Aurigene for drug discovery and development and has previously worked with Genentech on the Hedgehog pathway asset Erivedge. Clinical trial sites investigators and health care providers also represent customers as they conduct the studies that generate data for regulatory review. Should emavusertib reach market the end users would include oncology specialists hematologists and hospitals treating lymphoma leukemia and related conditions.

Investment Thesis

▲ Bull case

Curis has a compelling opportunity to redefine the treatment paradigm for chronic lymphocytic leukemia (CLL) by leveraging emavusertib's unique mechanism of action in combination with BTK inhibitors to target the TLR/NF-kappaB pathway, a pathway not addressed by current standard therapies, which could unlock deep and durable responses in patients who have plateaued on BTK monotherapy, a population with significant unmet need and growing clinical interest as highlighted by key opinion leaders, and the company's focus on achieving complete remission or undetectable minimal residual disease (MRD) positions it to potentially enable time-limited therapy, reducing lifelong treatment burden and improving patient quality of life in a market where resistance and chronic toxicity remain major drawbacks of existing BTK inhibitors like zanubrutinib and ibrutinib.
The TakeAim CLL proof-of-concept study, designed to evaluate emavusertib in combination with zanubrutinib in patients who have achieved partial remission but failed to reach complete remission or MRD negativity on BTK monotherapy, is on track for initial patient dosing by mid-2026 with early data expected by December 2026, and the company's deliberate avoidance of patient-by-patient enrollment updates—while frustrating to some analysts—reflects operational discipline in a notoriously slow-enrolling ultra-rare disease space, where lumpiness in monthly accrual is expected and management's consistent assertion of being "on track" suggests confidence in hitting milestones without needing to over-communicate interim noise, thereby preserving focus on meaningful clinical endpoints rather than vanity metrics.
Financially, Curis has structured its January 2026 PIPE financing to include Series B warrants that could deliver up to $20.2 million in additional gross proceeds upon public announcement of dosing the fifth patient in the TakeAim CLL study, a milestone-triggered financing mechanism that non-dilutively extends the company's cash runway into the second half of 2027, de-risking near-term execution and allowing sustained investment in both the PCNSL registrational study and the CLL proof-of-concept effort without requiring a dilutive equity raise, a structural advantage that aligns investor incentives with clinical progress and reduces the likelihood of a cash crunch during critical data readouts.
The preclinical and emerging clinical rationale for emavusertib in CLL is strengthened by its demonstrated ability to inhibit IRAK1/4, thereby blocking TLR-mediated NF-kappaB activation—a key resistance mechanism in BTK inhibitor-treated patients—without overlapping toxicities such as bone marrow suppression when combined with agents like zanubrutinib, a differentiation that addresses a major limitation of BTK/BCL-2 combinations which carry high infection and cytopenia risks, positioning emavusertib-based regimens as potentially superior in safety and efficacy for achieving deep remissions in heavily pretreated or resistant CLL populations.
Beyond hematologic malignancies, the encouraging preliminary data from the gastric and esophageal cancer study combining emavusertib with FOLFOX and anti-PD-1 (with or without Herceptin) in 16 evaluable patients—showing a manageable toxicity profile and early signs of activity—suggests broader applicability of the IRAK1/4 inhibition platform in solid tumors, particularly where inflammation-driven NF-kappaB signaling plays a role, creating a potential optionality upside that management has not heavily promoted but could unlock future partnership or expansion opportunities if the signal holds in larger cohorts, thereby diversifying risk beyond the current lymphoma-focused pipeline.

Curis has a compelling opportunity to redefine the treatment paradigm for chronic lymphocytic leukemia (CLL) by leveraging emavusertib's unique mechanism of action in combination with BTK inhibitors to target the TLR/NF-kappaB pathway, a pathway not addressed by current standard therapies, which could unlock deep and durable responses in patients who have plateaued on BTK monotherapy, a population with significant unmet need and growing clinical interest as highlighted by key opinion leaders, and the company's focus on achieving complete remission or undetectable minimal residual disease (MRD) positions it to potentially enable time-limited therapy, reducing lifelong treatment burden and improving patient quality of life in a market where resistance and chronic toxicity remain major drawbacks of existing BTK inhibitors like zanubrutinib and ibrutinib.
The TakeAim CLL proof-of-concept study, designed to evaluate emavusertib in combination with zanubrutinib in patients who have achieved partial remission but failed to reach complete remission or MRD negativity on BTK monotherapy, is on track for initial patient dosing by mid-2026 with early data expected by December 2026, and the company's deliberate avoidance of patient-by-patient enrollment updates—while frustrating to some analysts—reflects operational discipline in a notoriously slow-enrolling ultra-rare disease space, where lumpiness in monthly accrual is expected and management's consistent assertion of being "on track" suggests confidence in hitting milestones without needing to over-communicate interim noise, thereby preserving focus on meaningful clinical endpoints rather than vanity metrics.
Financially, Curis has structured its January 2026 PIPE financing to include Series B warrants that could deliver up to $20.2 million in additional gross proceeds upon public announcement of dosing the fifth patient in the TakeAim CLL study, a milestone-triggered financing mechanism that non-dilutively extends the company's cash runway into the second half of 2027, de-risking near-term execution and allowing sustained investment in both the PCNSL registrational study and the CLL proof-of-concept effort without requiring a dilutive equity raise, a structural advantage that aligns investor incentives with clinical progress and reduces the likelihood of a cash crunch during critical data readouts.
The preclinical and emerging clinical rationale for emavusertib in CLL is strengthened by its demonstrated ability to inhibit IRAK1/4, thereby blocking TLR-mediated NF-kappaB activation—a key resistance mechanism in BTK inhibitor-treated patients—without overlapping toxicities such as bone marrow suppression when combined with agents like zanubrutinib, a differentiation that addresses a major limitation of BTK/BCL-2 combinations which carry high infection and cytopenia risks, positioning emavusertib-based regimens as potentially superior in safety and efficacy for achieving deep remissions in heavily pretreated or resistant CLL populations.
Beyond hematologic malignancies, the encouraging preliminary data from the gastric and esophageal cancer study combining emavusertib with FOLFOX and anti-PD-1 (with or without Herceptin) in 16 evaluable patients—showing a manageable toxicity profile and early signs of activity—suggests broader applicability of the IRAK1/4 inhibition platform in solid tumors, particularly where inflammation-driven NF-kappaB signaling plays a role, creating a potential optionality upside that management has not heavily promoted but could unlock future partnership or expansion opportunities if the signal holds in larger cohorts, thereby diversifying risk beyond the current lymphoma-focused pipeline.

▼ Bear case

Curis faces substantial execution risk in its TakeAim CLL proof-of-concept study, as the trial targets a narrowly defined population—patients on BTK inhibitor monotherapy who have achieved partial remission but failed to reach complete remission or MRD negativity—a group that may be smaller and harder to identify than anticipated due to stringent eligibility criteria, inconsistent MRD testing standards across sites, and the fact that many such patients may already be switched to alternative therapies like venetoclax-based combinations, potentially slowing enrollment beyond the "lumpy" pace management acknowledges and jeopardizing the mid-2026 dosing target for the first five patients and the December 2026 initial data readout.
The company's reliance on emavusertib's ability to inhibit the TLR/NF-kappaB pathway as a differentiating mechanism in CLL remains largely preclinical, with no clinical data yet demonstrating that adding emavusertib to BTK inhibitors actually overcomes resistance or leads to superior complete remission or MRD-negative rates compared to BTK monotherapy or emerging BTK/BCL-2 regimens, and the absence of any discussion about comparative efficacy benchmarks or plans for head-to-head validation raises concerns that the biological hypothesis may not translate into meaningful clinical benefit, especially given the high bar set by current combinations that already achieve deep responses in subsets of patients.
Curis disclosed that the increase in its Q1 FY26 net loss to $24.2 million (from $10.6 million in Q1 FY25) was primarily driven by a change in fair value of warrant liabilities tied to the January 2026 PIPE financing, a non-cash accounting item that, while not affecting operational burn, obscures the underlying cash usage trend and may signal investor skepticism about the company's valuation, as such fluctuations often reflect market pricing of downside protection features in the warrants, suggesting that external investors embedded significant risk premiums in the financing structure.
Despite management's optimism about the PCNSL registrational study, the expectation of providing a "substantial update on enrollment" in the first half of 2027—rather than efficacy data—highlights the immense challenge of recruiting in primary CNS lymphoma, an ultra-orphan indication with limited patient pool and geographic dispersion, and the repeated emphasis on enrollment milestones over clinical endpoints suggests that meaningful efficacy readouts may be further out than implied, increasing the risk that the program fails to deliver a sufficiently compelling dataset for accelerated approval even if fully enrolled, particularly without a control arm in the single-arm design.
The company has not addressed potential competitive threats from next-generation BTK inhibitors or emerging targeted degraders (e.g., BTK PROTACs) that may offer superior target inhibition or alternative resistance mechanisms, nor has it discussed how emavusertib combinations would fare against venetoclax-based regimens—which are increasingly used early in CLL and achieve high MRD negativity rates—raising the possibility that by the time Curis generates pivotal data, the therapeutic landscape may have evolved beyond the relevance of its dual-blockade approach, especially if resistance mechanisms shift away from TLR/NF-kappaB dependence.

Curis faces substantial execution risk in its TakeAim CLL proof-of-concept study, as the trial targets a narrowly defined population—patients on BTK inhibitor monotherapy who have achieved partial remission but failed to reach complete remission or MRD negativity—a group that may be smaller and harder to identify than anticipated due to stringent eligibility criteria, inconsistent MRD testing standards across sites, and the fact that many such patients may already be switched to alternative therapies like venetoclax-based combinations, potentially slowing enrollment beyond the "lumpy" pace management acknowledges and jeopardizing the mid-2026 dosing target for the first five patients and the December 2026 initial data readout.
The company's reliance on emavusertib's ability to inhibit the TLR/NF-kappaB pathway as a differentiating mechanism in CLL remains largely preclinical, with no clinical data yet demonstrating that adding emavusertib to BTK inhibitors actually overcomes resistance or leads to superior complete remission or MRD-negative rates compared to BTK monotherapy or emerging BTK/BCL-2 regimens, and the absence of any discussion about comparative efficacy benchmarks or plans for head-to-head validation raises concerns that the biological hypothesis may not translate into meaningful clinical benefit, especially given the high bar set by current combinations that already achieve deep responses in subsets of patients.
Curis disclosed that the increase in its Q1 FY26 net loss to $24.2 million (from $10.6 million in Q1 FY25) was primarily driven by a change in fair value of warrant liabilities tied to the January 2026 PIPE financing, a non-cash accounting item that, while not affecting operational burn, obscures the underlying cash usage trend and may signal investor skepticism about the company's valuation, as such fluctuations often reflect market pricing of downside protection features in the warrants, suggesting that external investors embedded significant risk premiums in the financing structure.
Despite management's optimism about the PCNSL registrational study, the expectation of providing a "substantial update on enrollment" in the first half of 2027—rather than efficacy data—highlights the immense challenge of recruiting in primary CNS lymphoma, an ultra-orphan indication with limited patient pool and geographic dispersion, and the repeated emphasis on enrollment milestones over clinical endpoints suggests that meaningful efficacy readouts may be further out than implied, increasing the risk that the program fails to deliver a sufficiently compelling dataset for accelerated approval even if fully enrolled, particularly without a control arm in the single-arm design.
The company has not addressed potential competitive threats from next-generation BTK inhibitors or emerging targeted degraders (e.g., BTK PROTACs) that may offer superior target inhibition or alternative resistance mechanisms, nor has it discussed how emavusertib combinations would fare against venetoclax-based regimens—which are increasingly used early in CLL and achieve high MRD negativity rates—raising the possibility that by the time Curis generates pivotal data, the therapeutic landscape may have evolved beyond the relevance of its dual-blockade approach, especially if resistance mechanisms shift away from TLR/NF-kappaB dependence.

Counterparty Name Breakdown of Revenue (2025)

Peer group

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	match	Market Cap	P/E	P/S	Total Debt (Qtr)
1	AMGN	Amgen Inc	primary	211.73 Bn	24.22	5.56	62.75 Bn
2	GILD	Gilead Sciences, Inc.	primary	180.92 Bn	-62.49	5.94	28.66 Bn
3	VRTX	Vertex Pharmaceuticals Inc / Ma	primary	132.16 Bn	30.00	10.50	-
4	REGN	Regeneron Pharmaceuticals, Inc.	primary	82.89 Bn	19.15	5.34	1.99 Bn
5	ARGX	Argenx Se	primary	61.41 Bn	35.80	11.75	-
6	MRNA	Moderna, Inc.	primary	53.99 Bn	-17.13	24.23	0.59 Bn
7	ALNY	Alnylam Pharmaceuticals, Inc.	primary	34.48 Bn	44.51	7.18	-
8	BIIB	Biogen Inc.	primary	31.15 Bn	37.32	3.11	8.09 Bn

Curis CRIS

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Counterparty Name Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password